NovoCure reports record FY2025 revenue $655M (+8% YoY); appoints Frank Leonard as CEO

NovoCure Ltd

2025-FY EPS reported -$1.22 revenue$655,353,000

Preliminary FY2025 net revenue $655.4M (+8% YoY); Q4 revenue $174.4M (+8% YoY).
Cash and investments $448.3M after repaying $561M convertible notes due Nov 2025.
Active TTFields patients reached 4,620 globally; Optune Gio prescriptions +6% in Q4.
Frank Leonard, previously President, appointed CEO in December 2025.
Filed PMA for TTFields in brain metastases from NSCLC; topline data expected Q1-Q2 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.